International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 001-010
| Back | Table of Contents | PDF | Mail to Author | |
The Relationship of Ribosomal Protein L10 (RPL10) and L41 (RPL41) with Breast Cancer Molecular Subtypes
Sebati Sinan URKMEZ1, Birsen BILGICI1, Yurdanur SULLU2, Bekir KURU3, Necati OZEN4, Leman TOMAK5, Mehmet Alper ARSLAN6
1Ondokuz Mayis University, Faculty of Medicine, Department of Medical Biochemistry
2Ondokuz Mayis University, Faculty of Medicine, Department of Pathology
3Atasam Medical Center, Department of General Surgery
4VM Medical Park Hospital, Department of General Surgery
5Ondokuz Mayis University, Faculty of Medicine, Department of Biostatistics
6Ondokuz Mayis University, Faculty of Medicine, Department of Medical Biology
Keywords: Breast cancer, Gene expression, RPL10, RPL41
Breast cancer represents the most prevalent cancer type among women globally. Accurate molecular subtyping of breast cancer plays a vital role in determining optimal treatment strategies. Therefore, the main objective of this observational study is to investigate the correlation between breast cancer and its molecular subtypes with ribosomal proteins L10 and L41 at the level of gene expression. A total of 58 cancer patient samples, along with 16 healthy controls, were utilized. The samples were classified into molecular subtypes based on immunohistochemistry analysis. Tissue samples were subjected to RT-qPCR analysis for measurement the gene expression levels of RPL10 and RPL41. The findings revealed no significant differences in RPL10 gene expression across molecular subgroups of breast cancer. However, a significant decrease in RPL41 gene expression by 0.253-fold (p< 0.05) in the HER2-rich subtype and 0.257-fold (p< 0.05) in the TNBC subtype was observed compared to the control group. Additionally, RPL41 gene expression was significantly downregulated by 0.37-fold (p< 0.05) in the whole breast cancer group. In conclusion, the study results indicate a significant downregulation of RPL41 gene expression in the HER2-rich and triple-negative breast cancer (TNBC) breast cancer subtypes, as well as in the overall breast cancer cohort. To better understand the roles of RPL41 and RPL10 in cancer biology, further comprehensive investigations, including functional studies and mechanistic experiments, are needed.
Sebati Sinan URKMEZ1, Birsen BILGICI1, Yurdanur SULLU2, Bekir KURU3, Necati OZEN4, Leman TOMAK5, Mehmet Alper ARSLAN6
1Ondokuz Mayis University, Faculty of Medicine, Department of Medical Biochemistry
2Ondokuz Mayis University, Faculty of Medicine, Department of Pathology
3Atasam Medical Center, Department of General Surgery
4VM Medical Park Hospital, Department of General Surgery
5Ondokuz Mayis University, Faculty of Medicine, Department of Biostatistics
6Ondokuz Mayis University, Faculty of Medicine, Department of Medical Biology
Keywords: Breast cancer, Gene expression, RPL10, RPL41
Breast cancer represents the most prevalent cancer type among women globally. Accurate molecular subtyping of breast cancer plays a vital role in determining optimal treatment strategies. Therefore, the main objective of this observational study is to investigate the correlation between breast cancer and its molecular subtypes with ribosomal proteins L10 and L41 at the level of gene expression. A total of 58 cancer patient samples, along with 16 healthy controls, were utilized. The samples were classified into molecular subtypes based on immunohistochemistry analysis. Tissue samples were subjected to RT-qPCR analysis for measurement the gene expression levels of RPL10 and RPL41. The findings revealed no significant differences in RPL10 gene expression across molecular subgroups of breast cancer. However, a significant decrease in RPL41 gene expression by 0.253-fold (p< 0.05) in the HER2-rich subtype and 0.257-fold (p< 0.05) in the TNBC subtype was observed compared to the control group. Additionally, RPL41 gene expression was significantly downregulated by 0.37-fold (p< 0.05) in the whole breast cancer group. In conclusion, the study results indicate a significant downregulation of RPL41 gene expression in the HER2-rich and triple-negative breast cancer (TNBC) breast cancer subtypes, as well as in the overall breast cancer cohort. To better understand the roles of RPL41 and RPL10 in cancer biology, further comprehensive investigations, including functional studies and mechanistic experiments, are needed.
| Back | Table of Contents | PDF | Mail to Author | |